Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy

Cancer Research

Volumn 62, Issue 20, 2002, Pages 5853-5858

  Tatsumi, Tomohide ^a   Gambotto, Andrea ^a   Robbins, Paul D ^a   Storkus, Walter J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPITOPE; INTERLEUKIN 18; PEPTIDE;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER IMMUNOLOGY; CANCER INHIBITION; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE TRANSFER; IMMUNIZATION; MIXED LYMPHOCYTE REACTION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TH1 CELL; TUMOR IMMUNITY; TUMOR REJECTION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; GENE TRANSFER TECHNIQUES; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERLEUKIN-18; MICE; MICE, INBRED BALB C; SARCOMA, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

EID: 0037108707     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Steinman, R. M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol., 9: 271-296, 1991.
2. Hart, D. N. Dendritic cells: Unique leukocyte populations which control the primary immune response. Blood, 90: 3245-3287, 1997.
3. + T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens. Cancer Res., 54: 1055-1058, 1994.
4. Fields, R. C., Shimizu, K., and Mule, J. J. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune response in vitro and in vivo. Proc. Natl. Acad. Sci. USA, 95: 9482-9487, 1998.
5. Porgador, A., Snyder, D., and Gilboa, E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol., 156: 2918-2926, 1996.
6. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Jr., Melief, C. J., Ildstad, S. T., Kast, W. M., Deleo, A. B., and Lotze, M. T. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptide elicit protective and therapeutic antitumor immunity. Nat. Med., 12: 1297-1302, 1995.
7. Paglia, P., Chiodoni, C., Rodolfo, M., and Colombo, M. P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med., 183: 317-322, 1996.
8. Boczkowski, D., Nair, S. K., Snyder, D., and Gilboa, E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med., 184: 465-472, 1996.
9. Manickan, E., Kanangat, S., Rouse, R. J., Yu, Z., and Rouse, B. T. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. J. Leukocyte Biol., 61: 125-132, 1997.
10. Condon, C., Watkins, S. C., Celluzzi, C. M., Thompson, K., and Falo, L. D., Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med., 2: 1122-1128, 1996.
11. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., and Levy, R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2: 52-58, 1996.
12. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
13. Salgaller, M. L., Tjoa, B. A., Lodge, P. A., Ragde, H., Kenny, G., Boynton, A., and Murphy, G. P. Dendritic cell-based immunotherapy of prostate cancer. Crit. Rev. Immunol., 18: 109-119, 1998.
14. Kugler, A., Stuhler, G., Walden, P., Zoller, G., Zobywalski, A., Brossart, P., Trefzer, U., Ullrich, S., Muller, C. A., Becker, V., Gross, A. J., Hemmerlein, B., Kanz, L., Muller, G. A., and Ringert, R. H. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med., 6: 332-336, 2000.
15. Okamura, H., Tsutsui, H., Komatsu, T., Yutsudo, M., Hakura, A., Tanimoto, T., Torigoe, K., Okura, T., Nukada, Y., and Hattori, K. Cloning of a new cytokine that induces IFNγ production by T cells. Nature (Lond.), 378: 88-91, 1995.
16. Kohno, K., Kataoka, J., Ohtsuki, T., Suemoto, Y., Okamoto, I., Usui, M., Ikeda, M., and Kurimoto, M. IFN-γ-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J. Immunol., 158: 1541-1550, 1997.
17. Tsutsui, H., Matsui, K., Kawada, N., Hyodo, Y., Hayashi, N., Okamura, H., Higashino, K., and Nakanishi, K. IL-18 accounts for both TNF-α and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J. Immunol., 159: 3961-3967, 1997.
18. Micallef, M. J., Tanimoto, T., Kohno, K., Ikeda, M., and Kurimoto, M. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res., 57: 4557-4563, 1997.
19. Osaki, T., Peron, J. M., Cai, Q., Okamura, H., Robbins, P. D., Kurimoto, M., Lotze, M. T., and Tahara, H. IFN-γ inducing factor/IL-18 administration mediates IFN-γ- and IL-12-independent antitumor effect. J. Immunol., 160: 1742-1749, 1998.
20. Nakamura, S., Otani, T., Ijiri, Y., Motoda, R., Kurimoto, M., and Orita K. IFN-γ-dependent and -independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12. J. Immunol., 164: 3330-3336, 2000.
21. Mayordomo, J. I., Loftus, D. J., Sakamoto, H., De Cesare, C. M., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E., and DeLeo, A. B. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med., 183: 1357-1365, 1996.
22. DeLeo, A. B., Jay, G., Appela, E., DuBois, G. C., Law, L. W., and Old, L. J. Identification of a transformation-related protein in chemically induced sarcoma and other transformed cells of mouse. Proc. Natl. Acad. Sci. USA, 76: 2420-2424, 1979.
23. Son, Y. I., Egawa, S., Tatsumi, T., Redlinger, R. E., Kalinski, P., and Kanto, T. A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells. J. Immunol. Methods, 262: 145-157, 2002.
24. , Osaki, T., Hashimoto, W., Gambotto, A., Okamura, H., Robbins, P. D., Kurimoto, M., Lotze, M. T., and Tahara, H. Potent antitumor effect mediated by local expression of the mature form of the interferon-γ inducing factor, interleukin-18 (IL-18). Gene Ther., 6: 808-815, 1999.
25. Hardy, S., Kitamura, M., Harris-Stansil, T., Dai, Y., and Phippes, M. L. Construction of adenovirus vectors through Cre-lox recombination. J. Virol., 71: 1842-1849, 1997.
26. Tatsumi, T., Takehara, T., Kanto, T., Miyagi, T., Kuzushita, N., Sugimoto, Y., Jinushi, M., Kasahara, A., Sasaki, Y., Hori, M., and Hayashi, N. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res., 60: 7563-7567, 2001.
27. Storkus, W. J., Zeh, H. J., III, Salter, R. D., and Lotze, M. T. Identification of T-cell epitopes: Rapid isolation of class I-presented peptides from viable cells by mild acid elution. J. Immunother., 14: 94-103, 1993.
28. Nakanishi, K., Yoshimoto, T., Tsutsui, H., and Okamura, H. Interleukin-18 regulates both TH1 and TH2 responses. Annu. Rev. Immunol., 19: 423-474, 2001.
29. Zitvogel, L., Mayordomo, J. L., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T., and Storkus, W. J. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell I-associated cytokines. J. Exp. Med., 183: 87-97, 1996.
30. Gerosa, F., Baldani-Guerra, B., Nisii, C., Marchesini, V., Carra, G., and Trinchieri, G. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med., 195: 327-333, 2002.
31. Pardoll, D. M. Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. USA, 96: 5340-5342, 1999.
32. Overwijk, W. W., Lee, D. S., Surman, D. R., Irvine, K. R., Touloukian, C. E., Chan, C. C., Carrol, M. W., Moss, B., Rosenberg, S. A., and Restifo, N. P. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vilitigo and tumor cell destruction in mice: Requirement of CD4+ T lymphocytes. Proc. Natl. Acad. Sci. USA, 96: 2982-2987, 1999.
33. Rosenberg, S. A., and White, D. E. Vilitigo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphas. Tumor Immunol., 19: 81-84, 1996.
34. Parmiami, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, F. M., and Anichini, A. Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going? J. Natl. Cancer Inst. (Bethesda), 94: 805-818, 2002.